Novartis posts results of Phase 3 KLU156 trial in uncomplicated P. Falciparum malaria
The study, led by Novartis Pharmaceuticals, enrolled 1720 participants and completed enrollment on March 7, 2024, with primary completion on June 27, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026, confirming the efficacy, safety and tolerability of KLU156 compared with Coartem in adults and children.
Primary source
ClinicalTrials.gov results record, November 4, 2026
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
Read the source: Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation